SubjectWell Begins International Expansion with UK, Ireland, and South Africa
SubjectWell, the patient recruitment vendor, announced it has expanded its patient recruitment services into the United Kingdom, Ireland and South Africa. Supplementing its current footprint in the U.S. and Canada, the expansion is part of SubjectWell’s efforts to meet the needs of its pharmaceutical and clinical trial sponsors running global clinical trials, all while continuing to accelerate last patient in (LPI) by increasing awareness of clinical research in the general population and only charging for those patients who randomize.
“With 86 percent of clinical trials operating sites outside of the U.S., a more streamlined and complete risk-free patient recruitment offering with global reach was something our partners consistently requested,” said Ivor Clarke, CEO, SubjectWell. “We look forward to the continued growth of our business in 2020 and beyond, which will introduce millions of people to potentially life-changing clinical trial opportunities.
To further ease the recruitment process and to accommodate sites and sponsors worldwide, SubjectWell has met regulatory framework by complying with the specific requirements for any information collected, such as the requirements of the EU General Data Protection Regulation (GDPR). Under the terms of GDPR, organizations ensure that personal data is gathered with clear disclosures and under strict conditions, protecting businesses and patients alike.
SubjectWell will continue to expand into additional international markets in 2020, strengthening its commitment to serving as a single partner and offering global services to its contract research organizations and sponsors.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
